Table 2. Correlation between MYL9 expression and clinicopathological characteristics of ESCC.
| Characteristic | MYL9 expression | p | ||
|---|---|---|---|---|
| Low | High | |||
| No.cases (%) | No.cases (%) | |||
| Gender | Male | 47(72.3) | 47(66.2) | 0.463 |
| Female | 18(27.7) | 24(33.8) | ||
| Age (years) | <60 | 36(55.4) | 36(50.7) | 0.61 |
| ≥60 | 29(44.6) | 35(49.3) | ||
| Clinical stage | I-II | 37(56.9) | 38(53.5) | 0.732 |
| III | 28(43.1) | 33(46.5) | ||
| T classification | T1-T2 | 15(23.1) | 18(25.4) | 0.842 |
| T3-T4 | 50(76.9) | 53(74.6) | ||
| N classification | N0 | 34(52.3) | 33(46.5) | 0.607 |
| N1-2 | 31(47.7) | 38(53.5) | ||
| Differentiation | Well or Moderate | 53(81.5) | 46(64.8) | 0.028 |
| Poor | 12(18.5) | 25(35.2) | ||
| Location | Upper | 7(10.8) | 3(4.2) | 0.317 |
| Middle | 42(64.6) | 47(66.2) | ||
| Lower | 16(24.6) | 21(29.6) | ||
| Recurrence | No | 37(56.9) | 20(28.2) | 0.01 |
| Yes | 28(43.1) | 51(71.8) | ||
| Vital status | Alive | 44(67.7) | 23(32.4) | <0.01 |
| (at follow-up) | Death (tumor-related) | 21(32.3) | 46(64.8) | |
| Death (tumor-unrelated) | 0(0) | 2(2.8) | ||
| Therapy | Surgery only | 62(95.4) | 67(94.4) | 0.549 |
| Surgery+CT or RT or CRT | 3(4.6) | 4(5.6) | ||
p-values were analyzed by χ2 test or Fisher’s exact test, as appropriate.
Abbreviations: CT, chemotherapy; RT, radiotherapy; CRT, combination of CT and RT (chemoradiotherapy).